BiotechTube

Dinutuximab

Pre-clinicalTerminated
1 views this week 0 watching💤 Quiet
Interest: 15/100
15
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neuroblastoma

Conditions

Neuroblastoma

Trial Timeline

Mar 15, 2016 → Dec 19, 2016

NCT ID
NCT02693171

About Dinutuximab

Dinutuximab is a pre-clinical stage product being developed by United Therapeutics for Neuroblastoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02693171. Target conditions include Neuroblastoma.

What happened to similar drugs?

0 of 1 similar drugs in Neuroblastoma were approved

Approved (0) Terminated (0) Active (1)
🔄18F-MFBGIlluminaPhase 3

Hype Score Breakdown

Clinical
3
Activity
0
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02693171Pre-clinicalTerminated

Competing Products

20 competing products in Neuroblastoma

See all competitors
ProductCompanyStageHype Score
LY3295668 Erbumine + Topotecan + CyclophosphamideEli LillyPhase 1
33
ZD6474 + Retinoic AcidAstraZenecaPhase 1
21
Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acidAstraZenecaPhase 2
35
PRRT with 177Lu-DOTATATENovartisPhase 1
36
Topotecan + Temozolomide + RibociclibNovartisPhase 1
21
Topotecan hydrochlorideNovartisPhase 2
35
Ribociclib + CeritinibNovartisPhase 1
21
Bevacizumab + Temozolomide + Temozolomide + Irinotecan + Bevacizumab + Topotecan + Temozolomide + Dinutuximab Beta + CyclophosphamideRochePhase 2
39
GPC2 CAR T cellsGilead SciencesPhase 1
36
lorlatinibPfizerPre-clinical
18
Lorlatinib + Cyclophosphamide + Topotecan + Filgrastim/pegfilgrastimPfizerPhase 1
29
Nifurtimox + Cyclophosphamide + TopotecanBayerPhase 2
32
Dinutuximab with ChemotherapyUnited TherapeuticsPhase 1
30
ch14.18 -NCI + ch14.18-UTC + Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) + Aldesleukin (IL-2) + IsotretinoinUnited TherapeuticsPhase 1/2
29
Dinutuximab + Irinotecan Hydrochloride + Sargramostim + Temozolomide + TemsirolimusUnited TherapeuticsPhase 2
32
Dinutuximab + NK Cells + LenalidomideUnited TherapeuticsPhase 1
30
MAb-3F8 + Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) + 13-cis-Retinoic AcidUnited TherapeuticsPhase 2
24
Radiation: 131I-MIBG + Dinutuximab + VorinostatUnited TherapeuticsPhase 2
39
Dinutuximab + Vorinostat + Sargramostim + Potassium IodideUnited TherapeuticsPhase 1
26
Universal Donor (UD) TGFβi NK Cells + Temozolomide + Irinotecan + Dinutuximab + GM-CSFUnited TherapeuticsPhase 2
39